From Disqualification to Shared Decision-Making: ACSM Publishes the Evidence Behind Updated Sports Cardiology Guidance

6 min read
A 12-paper series in Medicine & Science in Sports & Exercise® details the rationale behind the 2025 AHA/ACC scientific statement for competitive athletes with heart conditions 

INDIANAPOLIS — The American College of Sports Medicine® (ACSM) has published a compendium of 12 task force papers in Medicine & Science in Sports & Exercise® (MSSE) that provides the detailed rationale for the updated clinical considerations for competitive sports participation by athletes with cardiovascular abnormalities. Published as official ACSM pronouncements, the papers explain the evidence behind the 2025 scientific statement from the American Heart Association (AHA) and American College of Cardiology (ACC), which moved the field away from automatic medical disqualifications and toward athlete-centered shared decision-making. 

The compendium was written for clinicians who evaluate and treat competitive athletes and help them decide whether and how to keep competing: sports and general cardiologists; cardiology subspecialists; pediatric cardiologists; primary care sports medicine physicians; and general internists and pediatricians. For each condition, the papers explain what the evidence shows, why specific recommendations changed, and which questions still need research. 

“Updates to considerations for competitive sports participation for athletes with cardiovascular abnormalities have shifted away from a paternalistic and conservative practice of automatic medical disqualifications without including the voice of the athlete, to practices grounded in shared decision-making that are very much athlete-centered,” said Jonathan H. Kim, MD, MSc, FACC, FAHA, professor of medicine and founding director of Emory Sports Cardiology at Emory University in Atlanta. Dr. Kim chaired the writing group for the 2025 AHA/ACC statement and is lead author of the MSSE compendium. 

“In addition, data over the last 10 years have shown that risks for many cardiac conditions are not as high as previously believed,” Dr. Kim said. “The combination of these two principles has led to changes in clinical guidance that are provided in the 2025 AHA/ACC Scientific Statement and summarized in these Task Force documents along with detailed discussions of the rationale that led to updates.” 

A preamble introduces the 11 task force papers, each matched to a section of the 2025 statement. Each paper covers the background for the conditions included, the evidence supporting the changes and future research directions. In all, 49 experts in sports cardiology, sports medicine, exercise physiology and cardiovascular disease from nine countries contributed to the series. 

Key updates for clinicians 
  • Shared decision-making is now the preferred approach. Task Force 3 lays out the ethical case for replacing physician-only eligibility decisions with shared decision-making and discusses the potential legal implications. 
  • For many conditions, risk is lower than once believed. Newer data support individualized decisions for athletes once excluded by blanket restrictions, including those with hypertrophic cardiomyopathy and inherited arrhythmia conditions such as long QT syndrome. In addition, athletes who test positive for a hypertrophic cardiomyopathy gene variant but show no signs of the disease can take part in all competitive sports with appropriate clinical surveillance. 
  • Some athletes can return sooner to training after myocarditis. Athletes with preserved heart function at diagnosis may be considered for return to play as early as 4-6 weeks after symptoms resolve, when cardiac MRI shows resolution of all myocardial inflammation, and exercise testing shows no inducible ventricular arrhythmias. Previous guidance advised 3-6 months of exercise restriction. 
  • Pre-participation screening guidance has evolved. A focused history and physical exam remains the core of the pre-participation evaluation, and adding a 12-lead ECG is reasonable where resources and expertise permit. Screening programs should be planned to limit harms, including worsening health disparities. Because no screening approach fully prevents sudden cardiac arrest in athletes, every program needs a well-developed emergency action plan. 
  • More athletes with other conditions are covered. Masters athletes (age 35 and older), a group that earlier recommendations did not address, now have a dedicated task force covering coronary artery disease, atrial fibrillation, myocardial fibrosis, aortic enlargement and valve disease. The series also addresses pregnant competitive athletes, pulmonary embolism, hypertension, commotio cordis, performance-enhancing drugs, altitude and scuba diving. It classifies sports by collision and impact risk to guide decisions for athletes taking blood thinners. 
Why it matters, by specialty 
  • Sports and general cardiologists: Condition-by-condition evidence to guide shared decision-making conversations and return-to-play plans. 
  • Cardiology subspecialists: The rationale behind updated considerations for cardiomyopathies, arrhythmias and implantable defibrillators, channelopathies, valve disease, aortic disease and spontaneous coronary artery dissection. 
  • Pediatric cardiologists and pediatricians: Updated approaches for young athletes with congenital heart disease, channelopathies, Kawasaki disease and myocarditis, plus pre-participation evaluation of youth athletes. 
  • Primary care sports medicine physicians: Practical guidance on the pre-participation evaluation, athlete ECG interpretation and emergency action planning, often the first point of care when a concern arises. 
  • General internists: A dedicated framework for Masters athletes with coronary artery disease, atrial fibrillation and other conditions common in older competitors, along with updated guidance on hypertension. 

The authors describe the new recommendations as “a point in time in the continuum of our understanding of the cardiac risks associated with competitive sports participation.” Each task force paper ends with research priorities meant to inform future updates. 

As an ACSM official pronouncement, the compendium was reviewed for the college by members-at-large and the ACSM Pronouncements Committee. The compendium and all 11 task force papers are available at Acsm-msse.org. The 2025 AHA/ACC scientific statement was published in Circulation and the Journal of the American College of Cardiology. 

The series 
Paper DOI 
Compendium of Task Forces for Clinical Considerations for Competitive Sports Participation for Competitive Athletes with Cardiovascular Abnormalities 10.1249/MSS.0000000000004100 
Task Force 1: Sports Classifications 10.1249/MSS.0000000000004089 
Task Force 2: Clinical Considerations for the Pre-Participation Cardiac Evaluation of Competitive Athletes 10.1249/MSS.0000000000004090 
Task Force 3: Ethical and Legal Aspects of Sports Participation 10.1249/MSS.0000000000004091 
Task Force 4: Clinical Considerations for the Care of Athletes with Genetic Cardiomyopathies 10.1249/MSS.0000000000004092 
Task Force 5: Clinical Considerations for Myocarditis and Selected Cardiovascular Conditions, Including Valvular Heart Disease 10.1249/MSS.0000000000004093 
Task Force 6: Clinical Considerations for the Care of Competitive Athletes with Congenital Heart Disease 10.1249/MSS.0000000000004094 
Task Force 7: Clinical Considerations for the Care of Competitive Athletes with Aortopathy or Spontaneous Coronary Artery Dissection 10.1249/MSS.0000000000004095 
Task Force 8: Care of Competitive Athletes with Arrhythmias and Sudden Cardiac Arrest: Clinical Considerations and Electrocardiogram Interpretations 10.1249/MSS.0000000000004096 
Task Force 9: Clinical Considerations for the Care of Athletes with Cardiac Channelopathies 10.1249/MSS.0000000000004097 
Task Force 10: Clinical Considerations for the Care of Masters Athletes with Underlying Cardiovascular Disease 10.1249/MSS.0000000000004098 
Task Force 11: Additional Cardiac Conditions and Considerations in Competitive Athletes 10.1249/MSS.0000000000004099 

### 

About ACSM 
The American College of Sports Medicine® is the largest sports medicine and exercise science organization in the world, with nearly 50,000 members and certified professionals in more than 100 countries. Together, ACSM is committed to the mission of educating and empowering professionals to advance the science and practice of health and human performance. ACSM advocates for legislation to help the government and health community make physical activity a priority.

Media contact: Caitlin Kinser, CAE, Sr. Director, Marketing Strategy, ckinser@acsm.org

Share this post

Other Related News

Shape the future of ACSM certification. Explore opportunities with the ACSM Certification Board and apply now.
Find out how Standard 4.9 will change cancer care, making exercise assessment a crucial part of patient treatment protocols.

GSSI Pre-Conference

The Physiology of Hydration: More Than Water Alone

This session explores the physiology of hydration through an integrated lens—examining how carbohydrate, sodium, flavor, and fluid interact to influence intake, absorption, retention, and performance. We’ll review current research on fluid balance, osmotic drivers, and palatability, highlighting mechanisms that underpin voluntary intake and thermoregulation. Attendees will gain insight into individualized strategies, including sweat profiling and timing approaches, to optimize euhydration and mitigate performance decrements associated with >2% body-mass loss. Practical applications will be linked to laboratory- and field-based research, ensuring translation from bench to field. This pre-conference equips you with evidence-based tools to support athlete hydration across diverse environments and sporting contexts. 

Divider line green, blue, black
  • Session 1: Sweating the detail: New insights on hydration considerations for athlete performance
    • Lewis James, PhD, Associate Professor in Human Nutrition in the School of Sport, Exercise and Health Sciences at Loughborough University
  • Session 2: Functional ingredients in fluid replacement beverages for athletes
    • Lindsay Baker, PhD, Director at the Gatorade Sports Science Institute
  • Session 3: The hydration toolkit: Practical approaches to athlete support
    • Floris Wardenaar, PhD, Associate Professor at the College of Health Solutions at Arizona State University